The role of protein arginine methylation 5 in DNA damage repair and cancer therapy

Abstract

Protein arginine methylation, a post-translational modification (PTM), is fundamental in regulating protein function and stability. Among the nine protein methyl transferases (PRMT), PRMT5 plays a critical role in promoting oncogenic processes including tumor proliferation, invasiveness, immune escape and DNA damage repair through different signaling pathways. It is also a target in cancer therapy, with numerous inhibitors in clinical trial. In this review, we focus on the biological functions of PRMT5 in DNA damage repair and maintenance of genome stability in cancer, and summarize the development advance of PRMT5 inhibitors in cancer therapy.

Keywords

PRMT5 / DNA damage repair / Genome stability

References

[1] Bertino JR, Waud WR, Parker WB, Lubin M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. Cancer Biology & Therapy. 2011, 11(7): 627-632

[2] Che Y, Liu Y, Yao Y, et al. . Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer Journal. 2023, 13: 27

[3] Clarke, T.L/, Sanchez-Bailon. M.P., Chiang, K., Reynolds, J.J., Herrero-Ruiz, J., Bandeiras, T.M., Matias, P.M., Maslen, S.L., Skehel, J.M., Stewart, G.S., Davies C.C. (2017). PRMT5-Dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination. Mol Cell, 65(5): 900–916 e907.

[4] Du, C., Hansen, L.J., Singh, S.X., Wang, F., Sun, R., Moure, C.J., Roso, K., Greer. P.K., Yan, H., He, Y. (2019). A PRMT5-RNF168-SMURF2 axis controls H2AX proteostasis. Cell Reports, 28(12): 3199–3211 e3195.

[5] Du C, Li SW, Singh SX, Roso K, Sun MA, Pirozzi CJ, Yang R, Li JL, He Y. Epigenetic regulation of fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization. Molecular Cancer Research. 2021, 19(12): 2046-2056

[6] Du W, Amarachintha S, Erden O, Wilson A, Pang Q. The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation. Oncotarget. 2016, 7(37): 60005-60020

[7] Feustel K, Falchook GS. Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: A review. J Immunother Precis Oncol. 2022, 5(3): 58-67

[8] Fu S, Zheng Q, Zhang D, Lin C, Ouyang L, Zhang J, Chen L. Medicinal chemistry strategies targeting PRMT5 for cancer therapy. European Journal of Medicinal Chemistry. 2022, 244

[9] Ghorbani A, Jeddi-Tehrani M, Saidpour A, Safa M, Bayat AA, Zand H. PI3K/AKT and Mdm2 activation are associated with inhibitory effect of cAMP increasing agents on DNA damage-induced cell death in human pre-B NALM-6 cells. Archives of Biochemistry and Biophysics. 2015, 566: 58-66

[10] Guo Z, Zheng L, Xu H, Dai H, Zhou M, Pascua MR, Chen QM, Shen B. Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding. Nature Chemical Biology. 2010, 6(10): 766-773

[11] Hamard PJ, Santiago GE, Liu F, Karl DL, Martinez C, Man N, Mookhtiar AK, Duffort S, Greenblatt S, Verdun RE, Nimer SD. PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. Cell Reports. 2018, 24(10): 2643-2657

[12] Hwang JW, Cho Y, Bae GU, Kim SN, Kim YK. Protein arginine methyltransferases: Promising targets for cancer therapy. Experimental & Molecular Medicine. 2021, 53(5): 788-808

[13] Hwang JW, Kim SN, Myung N, Song D, Han G, Bae GU, Bedford MT, Kim YK. PRMT5 promotes DNA repair through methylation of 53BP1 and is regulated by Src-mediated phosphorylation. Commun Biol. 2020, 3(1): 428

[14] Kannan A, Bhatia K, Branzei D, Gangwani L. Combined deficiency of Senataxin and DNA-PKcs causes DNA damage accumulation and neurodegeneration in spinal muscular atrophy. Nucleic Acids Research. 2018, 46(16): 8326-8346

[15] Kim H, Ronai ZA. PRMT5 function and targeting in cancer. Cell Stress. 2020, 4(8): 199-215

[16] Kryukov GV, Wilson FH, Ruth JR, Paulk J, Tsherniak A, Marlow SE, Vazquez F, Weir BA, Fitzgerald ME, Tanaka M, Bielski CM, Scott JM, Dennis C, Cowley GS, Boehm JS, Root DE, Golub TR, Clish CB, Bradner JE, Hahn WC, Garraway LA. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016, 351(6278): 1214-1218

[17] Lim JH, Lee YM, Lee G, et al. . PRMT5 is essential for the eIF4E-mediated 5'-cap dependent translation. Biochemical and Biophysical Research Communications. 2014, 452(4): 1016-1021

[18] Liu S, Liu Z, Piao C, Zhang Z, Kong C, Yin L, Liu X. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer. Journal of Experimental & Clinical Cancer Research. 2022, 41(1): 293

[19] Motolani, A., Martin, M., Sun, M., Lu, T. (2021). The structure and functions of PRMT5 in human diseases. Life (Basel), 11(10).

[20] Musiani, D., Bok, J., Massignani, E., Wu, L., Tabaglio, T., Ippolito, M.R., Cuomo, A., Ozbek, U., Zorgati. H., Ghoshdastider, U., Robinson, R.C., Guccione, E., Bonaldi, T. (2019). Proteomics profiling of arginine methylation defines PRMT5 substrate specificity. Sci Signal, 12(575).

[21] Owens, J.L., Beketova, E., Liu, S., Tinsley, S.L., Asberry, A.M., Deng, X., Huang, J., Li, C., Wan, J., Hu, C.D. (2020). PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes. iScience, 23(1): 100750.

[22] Prabhu L, Martin M, Chen L, Demir O, Jin J, Huang X, Motolani A, Sun M, Jiang G, Nakshatri H, Fishel ML, Sun S, Safa A, Amaro RE, Kelley MR, Liu Y, Zhang ZY, Lu T. Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue. Genes Dis. 2023, 10(1): 267-283

[23] Rehman I, Basu SM, Das SK, Bhattacharjee S, Ghosh A, Pommier Y, Das BB. PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes. Nucleic Acids Research. 2018, 46(11): 5601-5617

[24] Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong B-C, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nature Communications. 2021, 12(1): 979

[25] Smith CR, Aranda R, Bobinski TP, Briere DM, Burns AC, Christensen JG, Clarine J, Engstrom LD, Gunn RJ, Ivetac A, Jean-Baptiste R, Ketcham JM, Kobayashi M, Kuehler J, Kulyk S, Lawson JD, Moya K, Olson P, Rahbaek L, Thomas NC, Wang X, Waters LM, Marx MA. Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5*MTA complex for the treatment of MTAP-deleted cancers. Journal of Medicinal Chemistry. 2022, 65(3): 1749-1766

[26] Tan DQ, Li Y, Yang C, Li J, Tan SH, Chin DWL, Nakamura-Ishizu A, Yang H, Suda T. (2019) PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells. Cell Reports, 26(9): 2316–2328 e2316.

[27] Wang Y, Hu W, Yuan Y. Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery. Journal of Medicinal Chemistry. 2018, 61(21): 9429-9441

[28] Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: From enigmatic functions to therapeutic targeting. Nature Reviews. Drug Discovery. 2021, 20(7): 509-530

[29] Wu Y, Wang Z, Han L, Guo Z, Yan B, Guo L, Zhao H, Wei M, Hou N, Ye J, Wang Z, Shi C, Liu S, Chen C, Chen S, Wang T, Yi J, Zhou J, Yao L, Zhou W, Ling R, Zhang J. PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer. Molecular Therapy. 2022, 30(7): 2603-2617

[30] Yuan Y, Nie H. Protein arginine methyltransferase 5: A potential cancer therapeutic target. Cellular Oncology (dordrecht). 2021, 44(1): 33-44